Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devic…
Medical - Devices
US, Marlborough [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 18.17 | 108.56 | 91.87 | |
| Graham Fair Price | 0.13 | 10.11 | 10.10 | |
| PEG | 0.00 | 0.00 | 0.00 | |
| Price/Book | 14.23 | 5.02 | 4.39 | |
| Price/Cash Flow | 905.60 | -1234.54 | 122.77 | |
| Prices/Earnings | 21.17 | 50.81 | 41.94 | |
| Price/Sales | 14.04 | 25.93 | 22.74 | |
| Price/FCF | 905.60 | -1234.54 | 122.77 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.81 | 0.69 | 0.69 | |
| Operating Margin | 14.63 | 0.18 | 0.16 | |
| ROA | -6.65 | 0.01 | 0.01 | |
| ROE | 0.03 | 0.02 | -5.72 | |
| ROIC | 0.02 | 0.02 | -10.30 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.16 | 0.02 | 665.97 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.16 | 0.19 | 18.66 | |
| EPS QOQ | 0.00 | 0.00 | 0.00 | |
| FCF QOQ | 0.40 | -1.12 | 177.65 | |
| Revenue QOQ | 0.06 | 0.04 | -37.36 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 194.91 | 190.65 | -2.19 | |
| Days Sales Outstanding (DSO) | 53.83 | 53.78 | -0.10 | |
| Inventory Turnover | 0.46 | 0.47 | 2.24 | |
| Debt/Capitalization | 0.33 | 0.36 | 7.83 | |
| Quick Ratio | 0.63 | 1.29 | 106.43 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 13.16 | 13.57 | 3.12 | |
| Cash | 0.59 | 2.76 | 368.26 | |
| Capex | -0.18 | -0.17 | 8.43 | |
| Free Cash Flow | 0.47 | -0.06 | -88.29 | |
| Revenue | 2.54 | 2.63 | 3.30 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Weak